Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses hair shedding while using dutasteride, with users suggesting it's a normal phase that may lead to regrowth. Additional treatments like minoxidil, GHK-CU, and keto shampoo are mentioned to help manage shedding and promote hair growth.

The conversation discusses the experience of using dutasteride for hair loss, highlighting an initial shedding phase that eventually led to improved hair density. The user advises others to persist through the shedding phase and mentions using finasteride and minoxidil as part of their treatment.

Suvomipic, previously known as PP405, is progressing to Phase 3 trials for hair loss treatment. Its effectiveness compared to existing treatments like Minoxidil and Finasteride is still uncertain.

The user is experiencing diffuse thinning after 10-11 months on oral finasteride and is concerned about whether this is a normal shedding phase. They have been using topical finasteride and minoxidil for over a year.

The user experienced significant hair regrowth using topical finasteride and minoxidil but faced a prolonged shedding phase, leading them to increase the finasteride dose and add oral dutasteride. Despite concerns about shedding, they remain hopeful for regrowth and are supplementing with Vitamin D.

Minoxidil increases blood supply to the scalp, strengthening dormant follicles and extending the growth phase, but may increase scalp activity that can be countered with DHT blockers. Women experiencing side effects from finasteride or dutasteride for hair loss might consider alternatives like estrogen, especially if on birth control.

The user experienced hair regrowth using finasteride every other day and topical minoxidil but is currently going through a shedding phase. Despite the shedding, progress is evident, and users suggest patience and possibly adding microneedling to improve results.

PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

A user shared their 6.5-month experience with topical finasteride (2%) and minoxidil (5%), noting initial progress followed by a significant shedding phase. Others in the conversation reassured that shedding is normal and suggested staying consistent with the treatment for potential regrowth.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

The user discovered they had been using fake minoxidil for almost two years, which stopped working, and switched to finasteride, which slowed hair loss. They recently started using real minoxidil and noticed a shedding phase, indicating it might be effective.

The user experienced significant hair improvement using topical Minoxidil and oral Finasteride, despite an initial shedding phase. They prefer oral Finasteride for convenience and are considering oral Minoxidil, while others in the conversation discuss potential side effects and personal experiences with these treatments.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

A 25-year-old experienced significant hair regrowth using 5% minoxidil for 9.5 months despite an initial shed and a second shedding phase lasting 3.5 months. They encourage others to persist with minoxidil treatment through shedding as regrowth can occur.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The conversation discusses hair regrowth while using finasteride and creatine, with some users experiencing shedding phases. Creatine is generally considered not to significantly affect hair loss, and users suggest sticking with the current regimen during shedding.

The conversation discusses the effects of stopping and restarting finasteride, including a significant hair shedding phase. The user experienced erection problems with a higher dose and is concerned about whether hair thickness will return after the shedding subsides.

The conversation discusses hair loss treatments, specifically the use of oral minoxidil and finasteride over two years. Users inquire about dosages, shedding phases, and results, with some noting visible hair regrowth.

The user experienced significant hair regrowth after two years using 1mg oral tablets of finasteride and minoxidil, with noticeable results at six months and minimal side effects. The user reported only one major shedding phase early on and is 26 years old.

The user is on month 5.5 of dutasteride and 6.5 of oral minoxidil, experiencing some shedding and seeking advice on when shedding typically occurs with dutasteride. They have noticed hair regrowth and are concerned about the shedding phase.

A 19-year-old started using finasteride and topical minoxidil with a dermaroller after experiencing hair loss since age 14. The shedding phase lasted about two and a half months and has since stabilized.

The user started oral minoxidil and finasteride in March and noticed significant hair density improvement by August, despite experiencing a shedding phase. They also take biotin and report no side effects except for more keratosis pilaris on their arms.

The user has been using oral finasteride since February 2025 and added oral minoxidil in March 2026, noticing significant regrowth but is concerned about recent hairline thinning, possibly due to a shedding phase. They are considering adding dutasteride and eventually getting a hair transplant for long-term density improvement.